Dividend+Policy+Case+-+Penn+Schumann[1]

Dividend+Policy+Case+-+Penn+Schumann[1] - George Liu, the...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
George Liu, the CEO of Penn Schumann was a creature of habit. Every month he and Jennifer Rodriquez, the company’s chief financial officer, met for lunch and an informal chat at Pierre’s. Nothing was ever discussed until George had finished his favorite escalope de foie gras chaude. At their last meeting in thoughtfully with his glass of Chateau Haut-Brion Blanc before suddenly asking, “What do you think we should be doing about our payout policy?” Penn Schumann was a large and successful pharmaceutical company. It had an enviable list of highly profitable drugs, many of which had 5 or more further years of patent protection. Earnings in the latest 4 years had increased rapidly, but it was difficult to see that such rates of growth could continue. The company had traditionally paid out about 40% of earning as dividends, though the figure in 2008 was only 35%. Penn was spending over $4 billion a year on R&D, but the strong operation cash flow and conservative dividend policy had resulted in a buildup of cash. Penn’s recent income statements, balance sheets, and cash flow statements are summarized in Tables 17-4 to 17-6. The problem, as Mr. Liu explained, was that Penn’s dividend policy was more conservative than that of its main competitors. “Share prices depend on dividends,” he said. “If we raise our dividend, we’ll raise our share price, and that’s the name of the game.” Ms. Rodriquez suggested that the real issue was how much cash the company wanted to hold. The current cash holding was more than adequate for the company’s immediate needs. On the other hand, the research staff had been analyzing a number of new compounds with promising applications in the treatment of liver diseases. If this research were to lead to a marketable product, Penn would need to make a large investment. In addition, the company might require cash for possible acquisitions in the biotech field. “What worries me,” Ms. Rodriquez said, “is that investors don’t give us credit for this and think that we are going to fritter away the cash on negative-NPV investments or easy living. I don’t think we should commit to paying out high dividends, but perhaps we could use some of our cash to repurchase stock.” “I don’t know where anyone gets the idea that we fritter away cash on easy living.” Replied Mr. Liu, as he took another sip of wine, “but I like the idea of buying back our stock. We can tell shareholders that we are so confident about the future that we believe buying our own stock is the best investment we can make.” He scribbled briefly on his napkin. “Suppose we bought back 50
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 6

Dividend+Policy+Case+-+Penn+Schumann[1] - George Liu, the...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online